rc 3095 has been researched along with Hormone-Dependent Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, YF; Wu, B; Xu, Y | 1 |
| Getzenberg, RH; Konety, BR | 1 |
| Groot, K; Halmos, G; Radulovic, S; Schally, AV; Szepeshazi, K | 1 |
2 review(s) available for rc 3095 and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
New agonist- and antagonist-based treatment approaches for advanced prostate cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Bombesin; Clinical Trials as Topic; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Octreotide; Oligopeptides; Peptide Fragments; Prostatic Neoplasms; Sermorelin | 2012 |
Novel therapies for advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Bombesin; Diet; Enzyme Inhibitors; Epoprostenol; Genetic Therapy; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Ornithine Decarboxylase Inhibitors; Peptide Fragments; Polyamines; Prostatic Neoplasms; Suramin; Vitamins | 1997 |
1 other study(ies) available for rc 3095 and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Topics: Animals; Antineoplastic Agents; Bombesin; ErbB Receptors; Estrogens; Female; Gastrin-Releasing Peptide; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Hormone-Dependent; Peptide Fragments; Peptides | 1992 |